Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting

被引:41
作者
White, WB
Giles, T
Bakris, GL
Neutel, JM
Davidai, G
Weber, MA
机构
[1] Univ Connecticut, Ctr Hlth, Pat & Jim Calhoun Cardiol Ctr, Div Hypertens & Clin Pharmacol,Sch Med, Farmington, CT 06030 USA
[2] LSU Med Ctr, Dept Cardiol, New Orleans, LA USA
[3] Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA
[4] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
[5] Boehringer Ingelheim Pharmaceut Ltd, Dept Med, Ridgefield, CT USA
[6] SUNY Downstate Med Sch, Dept Med, Brooklyn, NY USA
关键词
D O I
10.1016/j.ahj.2005.02.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Traditional clinical trials in hypertension measure the efficacy of anti hypertensive drugs but may not fully assess their effectiveness in clinical practice. Community-based trials can provide this information but are limited because usually they are of open-label design and potentially subject to observer bias. Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial. Methods; Patients with hypertension, either untreated or currently on treatment, were started on, or switched to the angiotensin receptor blocker telmisartan 40 mg daily; after 2 weeks, if office BP remained >= 140/85 mm Hg, the dose was increased to 80 mg, and if necessary, hydrochlorothiazide 12.5 mg was added after a further 4 weeks and continued for the final 4-week period. Baseline and treatment ABPM measurements were completed in 940 previously untreated patients and 675 previously treated patients. Results The average reduction of the entire cohort was - 10.7/-6.5 mm Hg (P <.0001; mean 24 hour BPs were reduced by 12/8 and 8/5 mm Hg in the untreated and previously treated patients, respectively). In contrast, the office BPs fell by an average of 23/12 and 17/10 mm Hg in previously untreated and treated patients. In 401 patients whose baseline 24-hour BP was >= 130/85 mm Hg, the mean decrease in 24-hour BP was 16.8/11.4 mm Hg. Based on ABPM criteria, the BP was fully controlled (< 130/85 mm Hg) in 70% of patients, and based on office measurement criteria (<140/90 mm Hg), in 79%. Conclusions Ambulatory BP monitoring demonstrated excellent control rates by telmisartan monotherapy or in combination with hydrochlorothiazide. Observer and measurement bias was substantial based on the changes from baseline by clinical measurements in contrast to ambulatory BP recordings. The successful use of this procedure in primary care research will create further opportunities to define the effectiveness of treatment in the environment in which it is customarily prescribed.
引用
收藏
页码:176 / 184
页数:9
相关论文
共 25 条
[1]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[2]   Blood pressure control by home monitoring: meta-analysis of randomised trials [J].
Cappuccio, FP ;
Kerry, SM ;
Forbes, L ;
Donald, A .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7458) :145-148A
[3]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[4]   A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].
Cohn, JN ;
Tognoni, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675
[5]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[6]   Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial [J].
Giles, TD ;
Bakris, GL ;
Smith, DHG ;
Davidai, G ;
Weber, MA .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (06) :460-466
[7]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[8]  
Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
[9]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[10]   2003 European society of hypertension -: European Society of Cardiology guidelines for the management of arterial hypertension [J].
Mancia, G ;
Rosei, EA ;
Cifkova, R ;
DeBacker, G ;
Erdine, S ;
Fagard, R ;
Farsang, C ;
Heagerty, AM ;
Kawecka-Jaszcs, K ;
Kiowski, W ;
Kjeldsen, S ;
Lüscher, T ;
McInnes, G ;
Mallion, JM ;
Brien, EO ;
Poulter, NR ;
Priori, SG ;
Rahn, KH ;
Rodicio, JL ;
Ruilope, LM ;
Safar, M ;
Staessen, JA ;
van Zwieten, P ;
Waeber, B ;
Williams, B ;
Zanchetti, A ;
Zannad, F .
JOURNAL OF HYPERTENSION, 2003, 21 (06) :1011-1053